Biggest News Aggregation in the World
📰 Trial Synopsis News

Trial Synopsis News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Trial Synopsis. Real-time updates on events, politics, business and more.

BerGenBio Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients

BerGenBio Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients Data receipt is ongoing and evaluation of efficacy data is underway Exploratory analyses are looking to define subsets of patients with baseline markers indicative of increased disease severity with the potential for greater benefit Bemcentinib was well tolerated throughout both studies, in the ACCORD2 study there was a numerically lower number of deaths up to day 29 in the ...
South Africa United Kingdom Chris Welsh Carina Jurs Mary Jane Elliott Richard Godfrey

BerGenBio Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients

Data receipt is ongoing and evaluation of efficacy data is underway Exploratory analyses are looking to define subsets of patients with baseline markers indicative of increased disease severity with the potential for greater benefit Bemcentinib was well tolerated throughout both studies, in the ACCORD2 study there was a numerically lower number of deaths up to day 29 in the bemcentinib arm (1 of 28 with bemcentinib + standard of care vs 5 of 32 in patients treated with standard of care alone)...
South Africa United Kingdom Chris Welsh Mary Jane Elliott Richard Godfrey Jan Petter

DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial Table: IMU-838 Shows Acceleration of Time to Clinical Improvement High-risk patients and patients aged over 65 years experienced a more substantial treatment benefit from IMU-838 than in the general patient population: - The 75% probability [5] to reach clinical improvement (based on investigator assessment) was accelerated by 3.8 days in IMU-838 trea...
United States Paula Schwartz Edna Kaplan Jessica Breu Andreas Muehler Daniel Vitt

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science